Advertisement

Topics

Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

07:23 EST 12 Feb 2018 | SCRIP

France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative...

      

Related Stories

 

Original Article: Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

NEXT ARTICLE

More From BioPortfolio on "Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...